Why the study?
The study was designed to critically appraise the methodology of the ongoing START YOUNG trial comparing TAVI with SAVR in patients aged 65-75 years with symptomatic severe AS.
Does transcatheter aortic valve implantation (TAVI) provide non-inferior outcomes compared to surgical aortic valve replacement (SAVR) in patients aged 65-75 years with symptomatic severe aortic stenosis?
Does transcatheter aortic valve implantation (TAVI) provide non-inferior outcomes compared to surgical aortic valve replacement (SAVR) in patients aged 65-75 years with symptomatic severe aortic stenosis?
The ongoing START YOUNG trial comparing TAVI to SAVR in younger patients requires significant methodological revisions to generate valid, guideline-informing evidence.
Answers are grounded in this paper and cite their sources.
Methodological flaws in START YOUNG warrant caution interpreting its results; leaves TAVI-SAVR non-inferiority open in patients aged 65-75.
OBJECTIVES: To critically appraise the design of the ongoing multicentre, randomized START YOUNG trial comparing transcatheter aortic valve implantation (TAVI) with bioprosthetic surgical aortic valve replacement (SAVR) in patients aged 65-75 years with symptomatic severe aortic stenosis (AS). METHODS: Publicly available trial information (ClinicalTrials.gov: NCT06861361) was reviewed, and the design was benchmarked against the minimum expected methodological standards for generating practice-changing evidence in patients with very long life expectancy (LE) following SAVR. The appraisal domains included objectives and study endpoints; selected non-inferiority (NI) margins; adequacy of follow-up for late events; statistical analysis plans and handling of crossovers/missing data; consistency of surgical comparators; and prespecified sub-groups. RESULTS: Several major concerns were identified: (1) co-primary safety/efficacy composites mix hard adverse events (death, stroke) with softer outcomes, with rehospitalization likely to dominate; (2) limited duration primary follow-up (30 days/1 year), with only optional survaillance beyond 5 years, inadequate for durability and late hazards; (3) wide NI margins (7%-8%) that could accept clinically meaningful inferiority; (4) an unclear statistical analysis plan; (5) a device-specific TAVI arm versus heterogeneous SAVR comparator; and (6) up to 25% bicuspid anatomy without stratified randomization or powered analyses. Collectively, these choices markedly increase the risks of type I error, and misinterpretation in a population with likely crossing hazard curves and a long median LE comparable to that of the age-matched general population after SAVR. CONCLUSIONS: In order to generate guideline-informing evidence for extending TAVI to younger patients with severe AS, the trial should prioritise hard adverse endpoints, tighten NI margins, mandate extended follow-up, standardise the surgical comparator, and adequately power the bicuspid subgroup. Without these revisions, continuing the study under the current protocol risks yielding biased, non-guideline informative results.
No takes yet. Share an insight, caveat, or question.
Milojevic et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: